ARGX-117, a therapeutic complement inhibiting antibody targeting C2

[1]  John D. Lambris,et al.  The first case of COVID-19 treated with the complement C3 inhibitor AMY-101 , 2020, Clinical Immunology.

[2]  David Berlin,et al.  Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: A report of five cases , 2020, Translational Research.

[3]  P. Marchetti,et al.  Eculizumab treatment in patients with COVID-19: preliminary results from real life ASL Napoli 2 Nord experience. , 2020, European review for medical and pharmacological sciences.

[4]  Wei Chen,et al.  Extensive Acute Lower Extremity Arterial Thrombosis: A Major Thrombus Formation Caused by COVID-19 , 2020, medRxiv.

[5]  John D Lambris,et al.  Clinical promise of next-generation complement therapeutics , 2019, Nature Reviews Drug Discovery.

[6]  J. Lambris,et al.  New insights into the immune functions of complement , 2019, Nature Reviews Immunology.

[7]  J. Marier,et al.  A Randomized, First‐in‐Human, Healthy Volunteer Trial of sutimlimab, a Humanized Antibody for the Specific Inhibition of the Classical Complement Pathway , 2018, Clinical pharmacology and therapeutics.

[8]  P. Stordeur,et al.  Quantification of human complement C2 protein using an automated turbidimetric immunoassay , 2018, Clinical chemistry and laboratory medicine.

[9]  John D Lambris,et al.  The renaissance of complement therapeutics , 2018, Nature Reviews Nephrology.

[10]  T. Yednock,et al.  Nonclinical Development of ANX005: A Humanized Anti-C1q Antibody for Treatment of Autoimmune and Neurodegenerative Diseases , 2017, International journal of toxicology.

[11]  J. Macneil,et al.  High Risk for Invasive Meningococcal Disease Among Patients Receiving Eculizumab (Soliris) Despite Receipt of Meningococcal Vaccine , 2017, MMWR. Morbidity and mortality weekly report.

[12]  J. Nezu,et al.  Long lasting neutralization of C5 by SKY59, a novel recycling antibody, is a potential therapy for complement-mediated diseases , 2017, Scientific Reports.

[13]  T. Igawa,et al.  Sweeping antibody as a novel therapeutic antibody modality capable of eliminating soluble antigens from circulation , 2016, Immunological reviews.

[14]  L. Isaac,et al.  Systemic Lupus Erythematosus and Deficiencies of Early Components of the Complement Classical Pathway , 2016, Front. Immunol..

[15]  T. Igawa,et al.  Calcium-dependent antigen binding as a novel modality for antibody recycling by endosomal antigen dissociation , 2015, mAbs.

[16]  S. Berentsen.  Role of Complement in Autoimmune Hemolytic Anemia , 2015, Transfusion Medicine and Hemotherapy.

[17]  G. Parry,et al.  TNT003, an inhibitor of the serine protease C1s, prevents complement activation induced by cold agglutinins. , 2014, Blood.

[18]  V. Holers.  Complement and its receptors: new insights into human disease. , 2014, Annual review of immunology.

[19]  Richard J. H. Smith,et al.  Generation of Multiple Fluid-Phase C3b:Plasma Protein Complexes during Complement Activation: Possible Implications in C3 Glomerulopathies , 2014, The Journal of Immunology.

[20]  J. Bernstein,et al.  Population pharmacokinetics of plasma-derived C1 esterase inhibitor concentrate used to treat acute hereditary angioedema attacks. , 2010, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[21]  M. Stegall,et al.  Sensitized renal transplant recipients: current protocols and future directions , 2010, Nature Reviews Nephrology.

[22]  A. Zanella,et al.  Complement fraction 3 binding on erythrocytes as additional mechanism of disease in paroxysmal nocturnal hemoglobinuria patients treated by eculizumab. , 2009, Blood.

[23]  R. Holgate,et al.  Circumventing immunogenicity in the development of therapeutic antibodies. , 2009, IDrugs : the investigational drugs journal.

[24]  R. Brodsky,et al.  Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria , 2007, Nature Biotechnology.

[25]  R. Ober,et al.  Divergent activities of an engineered antibody in murine and human systems have implications for therapeutic antibodies , 2006, Proceedings of the National Academy of Sciences.

[26]  R. Colvin,et al.  Antibody-mediated organ-allograft rejection , 2005, Nature Reviews Immunology.

[27]  P. Ward,et al.  Complement determinations in human disease. , 2004, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[28]  P. Parren,et al.  Effector Function Activities of a Panel of Mutants of a Broadly Neutralizing Antibody against Human Immunodeficiency Virus Type 1 , 2001, Journal of Virology.

[29]  J. Baars,et al.  Application of a monoclonal antibody against a neoepitope on activated C4 in an ELISA for the quantification of complement activation via the classical pathway. , 1993, Journal of immunological methods.

[30]  M. Frank,et al.  Activator-bound C1 is less susceptible to inactivation by C1 inhibition than is fluid-phase C1. , 1986, Journal of immunology.

[31]  J. Gelfand,et al.  Replacement therapy in hereditary angioedema: successful treatment of acute episodes of angioedema with partly purified C1 inhibitor. , 1980, The New England journal of medicine.